Kimberly Hudson, MD
Internal Medicine · Lexington, KYNPI 1538185897
Payments from drug & device makers
Across 217 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$429
- Lilly USA, LLC$402
- Novo Nordisk$394
- Pfizer$295
- Takeda Pharmaceuticals U.S.A., Inc.$235
- Corium, LLC$146
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,124100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $429 |
| Lilly USA, LLC | 24 | $402 |
| Novo Nordisk | 28 | $394 |
| Pfizer | 25 | $295 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $235 |
| Corium, LLC | 11 | $146 |
| Johnson & Johnson | 10 | $145 |
| GSK | 8 | $130 |
| Merck | 6 | $80 |
| Exact Sciences | 5 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $74 |
| Amgen | 4 | $62 |
| Biohaven Pharmaceuticals, Inc. | 4 | $60 |
| Genentech USA, Inc. | 5 | $58 |
| Astellas Pharma US Inc | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 4 | $50 |
| Novartis | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| AstraZeneca | 2 | $24 |
| Alkermes, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Agile Therapeutics, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Abbott | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Cranial Technologies, Inc | 1 | $14 |
| Tris Pharma Inc | 1 | $13 |
| Neos Therapeutics, LP | 1 | $13 |
| Bayer | 1 | $13 |
| Phadia US Inc. | 1 | $11 |
| Inogen, Inc. | 1 | $9 |
How this compares
$3,136 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 76 | $130,809 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 568 | $127,145 |
| JardianceEmpagliflozin | 86 | $111,338 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 345 | $107,515 |
| OzempicSemaglutide | 56 | $96,388 |
| MounjaroTirzepatide | 49 | $68,848 |
| EliquisApixaban | 96 | $59,290 |
| FarxigaDapagliflozin Propanediol | 31 | $43,236 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 377 | $26,436 |
| ProliaDenosumab | 14 | $24,677 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $7,548 |
| XareltoRivaroxaban | 12 | $6,684 |
| SynthroidLevothyroxine Sodium | 93 | $6,654 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,594 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix, Arexvy, Breo Ellipta | $130 | $240,591928 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $402 | $199,657125 claims |
| Boehringer IngelheimJardiance | $15 | $111,33886 claims |
| Novo NordiskOzempic | $394 | $96,38856 claims |
| PfizerEliquis | $295 | $59,29096 claims |
| AstraZenecaFarxiga, Symbicort | $24 | $50,78346 claims |
| AmgenProlia | $62 | $24,67714 claims |
| Johnson & JohnsonXarelto | $145 | $6,68412 claims |
| AbbVieSynthroid | $429 | $6,65493 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Lexington
- Neil FarrisLexington$3M
- David ManninoLexington$168K
- John BordersLexington$166K
- Fadi BachaLexington$31K
- James BordersLexington$31K
- Jad BalloutLexington$30K
- Thomas von UnrugLexington$22K
- Danilo CoralesLexington$17K
- Mohamed TashaniLexington$17K
- Kelli TrentLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.